共 50 条
- [21] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Taplin, Mary-Ellen论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAGleave, Martin论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAEvans, Christopher P.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAEfstathiou, Eleni论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAKantoff, Philip W.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USARoss, Ashley论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAShore, Neal D.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USABriganti, Alberto论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAHadaschik, Boris A.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAHeidenreich, Axel论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USARooney, Oliver Brendan论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USATian, Shaozhou Ken论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAWetherhold, Lisa论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAXu, Weichun论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USACheng, Shinta论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USAKibel, Adam S.论文数: 0 引用数: 0 h-index: 0机构: Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
- [22] A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study statusANNALS OF ONCOLOGY, 2020, 31 : S547 - S547De Giorgi, U.论文数: 0 引用数: 0 h-index: 0机构: Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, Italy Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalyShore, N.论文数: 0 引用数: 0 h-index: 0机构: Carolina Urol Res Ctr, Dept Urol, Myrtle Beach, SC USA Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalySridharan, S.论文数: 0 引用数: 0 h-index: 0机构: Calvary Mater Newcastle, Dept Radiat Oncol, Newcastle, NSW, Australia Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalyGleave, M.论文数: 0 引用数: 0 h-index: 0机构: Univ British Columbia, Vancouver Prostate Ctr, Dept Urol Sci, Vancouver, BC, Canada Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalyRosbrook, B.论文数: 0 引用数: 0 h-index: 0机构: Pfizer Inc, Dept Clin Stat, San Diego, CA USA Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalyShen, Q.论文数: 0 引用数: 0 h-index: 0机构: Pfizer Inc, Dept Global Clin Dev, Groton, CT 06340 USA Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalySugg, J.论文数: 0 引用数: 0 h-index: 0机构: Astellas Pharma Inc, Dept Biostat, Northbrook, IL USA Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalyHaas, G. P.论文数: 0 引用数: 0 h-index: 0机构: Astellas Pharma Inc, Dept Global Dev, Northbrook, IL USA Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, ItalyFreedland, S. J.论文数: 0 引用数: 0 h-index: 0机构: Cedars Sinai Med Ctr, Dept Med Oncol, Samuel Oschin Comprehens Canc Inst, Div Urol,Dept Surg,Durham VA Med Ctr, Los Angeles, CA 90048 USA Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Forli Cesena, Italy
- [23] CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancerANNALS OF ONCOLOGY, 2023, 34 : S1582 - S1583Matsubara, N.论文数: 0 引用数: 0 h-index: 0机构: Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan论文数: 引用数: h-index:机构:Smith, M. R.论文数: 0 引用数: 0 h-index: 0机构: Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Oncol, Boston, MA USA Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanMckay, R. R.论文数: 0 引用数: 0 h-index: 0机构: Univ Calif San Diego UCSD, Med, La Jolla, CA USA Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanTodenhofer, T.论文数: 0 引用数: 0 h-index: 0机构: Studienpraxis Urol, Clin Trial Unit, Nuertingen, Germany Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanPiulats Rodriguez, J. M.论文数: 0 引用数: 0 h-index: 0机构: Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Dept Med Oncol, Barcelona, Spain Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanChung, K. L.论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Oncol, New York, NY USA Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanHeirich, D.论文数: 0 引用数: 0 h-index: 0机构: Loxo Oncol Inc, Clin Sci, South San Francisco, CA USA Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanSherwood, S.论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Med, West Ryde, NSW, Australia Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanSchaverien, C.论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Oncol, Indianapolis, IN USA Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanFasnacht, N.论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly Suisse SA, Oncol Dept, Vernie, Switzerland Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanLithio, A.论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly & Co, Stat Dept, Indianapolis, IN USA Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanNacerddine, K.论文数: 0 引用数: 0 h-index: 0机构: Eli Lilly France, Global Clin Dev, Neuilly sur Seine, France Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, JapanZhang, T.论文数: 0 引用数: 0 h-index: 0机构: UT Southwestern Med Ctr, Simmons Comprehens Canc Ctr, Internal Med Dept, Dallas, TX USA Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan
- [24] TALAPRO-3: A phase III, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)ANNALS OF ONCOLOGY, 2021, 32 : S672 - S673论文数: 引用数: h-index:机构:Azad, A. A.论文数: 0 引用数: 0 h-index: 0机构: Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia Univ Utah Hlth, Huntsman Canc Inst, Clin Res Innovat, Salt Lake City, UT USA论文数: 引用数: h-index:机构:Shore, N. D.论文数: 0 引用数: 0 h-index: 0机构: Carolina Urol Res Ctr, Dept Urol, Myrtle Beach, SC USA Univ Utah Hlth, Huntsman Canc Inst, Clin Res Innovat, Salt Lake City, UT USAChakrabarti, J.论文数: 0 引用数: 0 h-index: 0机构: Pfizer Ltd, Oncol Drug Dev, Surrey, England Univ Utah Hlth, Huntsman Canc Inst, Clin Res Innovat, Salt Lake City, UT USAChen, H-C.论文数: 0 引用数: 0 h-index: 0机构: Pfizer Inc, Biostat, La Jolla, CA USA Univ Utah Hlth, Huntsman Canc Inst, Clin Res Innovat, Salt Lake City, UT USALanzalone, S.论文数: 0 引用数: 0 h-index: 0机构: Pfizer, Clin Dev Oncol, Milan, Italy Univ Utah Hlth, Huntsman Canc Inst, Clin Res Innovat, Salt Lake City, UT USANiyazov, A.论文数: 0 引用数: 0 h-index: 0机构: Pfizer Inc, Global HEOR, New York, NY USA Univ Utah Hlth, Huntsman Canc Inst, Clin Res Innovat, Salt Lake City, UT USASaad, F.论文数: 0 引用数: 0 h-index: 0机构: Univ Montreal, Ctr Hosp, Med Oncol, Montreal, PQ, Canada CRCHUM, Inst Canc Montreal, Montreal, PQ, Canada Univ Utah Hlth, Huntsman Canc Inst, Clin Res Innovat, Salt Lake City, UT USA
- [25] Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trialBMC Cancer, 18Lorenzo Tosco论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationAnnouschka Laenen论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationThomas Gevaert论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationIsabelle Salmon论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationChristine Decaestecker论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationElai Davicioni论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationChristine Buerki论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationFrank Claessens论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationJohan Swinnen论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationKarolien Goffin论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationRaymond Oyen论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationWouter Everaerts论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationLisa Moris论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationGert De Meerleer论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationKarin Haustermans论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and RegenerationSteven Joniau论文数: 0 引用数: 0 h-index: 0机构: University Hospitals Leuven,Urology, Department of Development and Regeneration
- [26] Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trialBMC CANCER, 2018, 18Tosco, Lorenzo论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, Belgium Katholieke Univ Leuven, Dept Imaging & Pathol, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumLaenen, Annouschka论文数: 0 引用数: 0 h-index: 0机构: Katholieke Univ Leuven, Leuven Biostat & Stat Bioinformat Ctr, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumGevaert, Thomas论文数: 0 引用数: 0 h-index: 0机构: Katholieke Univ Leuven, Lab Expt Urol, Organ Syst, Leuven, Belgium Katholieke Univ Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium AZ Klina, Dept Pathol, Brasschaat, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumSalmon, Isabelle论文数: 0 引用数: 0 h-index: 0机构: ULB, DIAPath, Ctr Microscopy & Mol Imaging, Gosselies, Belgium Univ Libre Bruxelles, Erasme Univ Hosp, Dept Pathol, Brussels, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumDecaestecker, Christine论文数: 0 引用数: 0 h-index: 0机构: ULB, DIAPath, Ctr Microscopy & Mol Imaging, Gosselies, Belgium ULB, Labs Image Signal Proc & Acoust, Brussels, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumDavicioni, Elai论文数: 0 引用数: 0 h-index: 0机构: Biosciences Inc, GenomeDX, Vancouver, BC, Canada Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumBuerki, Christine论文数: 0 引用数: 0 h-index: 0机构: Biosciences Inc, GenomeDX, Vancouver, BC, Canada Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumClaessens, Frank论文数: 0 引用数: 0 h-index: 0机构: Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumSwinnen, Johan论文数: 0 引用数: 0 h-index: 0机构: Katholieke Univ Leuven, Dept Oncol, Lab Lipid Metab & Canc, Leuven, Belgium Katholieke Univ Leuven, Univ Leuven, Leuven Canc Inst, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumGoffin, Karolien论文数: 0 引用数: 0 h-index: 0机构: Katholieke Univ Leuven, Dept Imaging & Pathol, Leuven, Belgium UZ Leuven, Nucl Med & Mol Imaging, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumOyen, Raymond论文数: 0 引用数: 0 h-index: 0机构: Gasthuisberg Univ Hosp Leuven, Dept Radiol, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumEveraerts, Wouter论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumMoris, Lisa论文数: 0 引用数: 0 h-index: 0机构: Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumDe Meerleer, Gert论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumHaustermans, Karin论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Leuven, Dept Radiat Oncol, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, BelgiumJoniau, Steven论文数: 0 引用数: 0 h-index: 0机构: Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, Belgium Univ Hosp Leuven, Dept Dev & Regenerat, Urol, Leuven, Belgium
- [27] A randomised double-blind placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancerEUROPEAN UROLOGY SUPPLEMENTS, 2008, 7 (03) : 231 - 231Horti, J.论文数: 0 引用数: 0 h-index: 0机构: Natl Inst Oncol, Dept Med Oncol, Budapest, Hungary Natl Inst Oncol, Dept Med Oncol, Budapest, HungaryWidmark, A.论文数: 0 引用数: 0 h-index: 0机构: Umea Univ Hosp, Dept Oncol, S-90185 Umea, Sweden Natl Inst Oncol, Dept Med Oncol, Budapest, HungaryStenzl, A.论文数: 0 引用数: 0 h-index: 0机构: Univ Tubingen, Dept Urol, Tubingen, Germany Natl Inst Oncol, Dept Med Oncol, Budapest, HungaryTuresson, I论文数: 0 引用数: 0 h-index: 0机构: Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden Natl Inst Oncol, Dept Med Oncol, Budapest, HungaryFederico, M. H.论文数: 0 引用数: 0 h-index: 0机构: Univ Sao Paulo, INRAD, Fac Med, Hosp Clini, Sao Paulo, Brazil Natl Inst Oncol, Dept Med Oncol, Budapest, HungaryAbratt, R. P.论文数: 0 引用数: 0 h-index: 0机构: New Groote Schuur Hosp, Dept Radiat Oncol, Cape Town, South Africa Natl Inst Oncol, Dept Med Oncol, Budapest, HungarySanders, N.论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca R&D, Biostat, Loughborough, Leics, England Natl Inst Oncol, Dept Med Oncol, Budapest, HungaryPover, G. M.论文数: 0 引用数: 0 h-index: 0机构: AstraZeneca, Alderley Pk, Macclefield, England Natl Inst Oncol, Dept Med Oncol, Budapest, HungaryBodrogi, L.论文数: 0 引用数: 0 h-index: 0机构: Natl Inst Oncol, Dept Med Oncol, Budapest, Hungary
- [28] Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II studyJOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Yang, T. S.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanOh, D. Y.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanGuimbaud, R.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanSzanto, J.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanSalek, T.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanThurzo, L.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanVieitez, J. M.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanPover, G. M.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, TaiwanKim, T. W.论文数: 0 引用数: 0 h-index: 0机构: Chang Gung Mem Hosp, Tao Yuan, Taiwan Seoul Natl Univ Hosp, Seoul 110744, South Korea Univ Toulouse, Ctr Hosp, Toulouse, France Univ Debrecen, H-4012 Debrecen, Hungary NCI, Bratislava, Slovakia Univ Med Sch Szeged, Szeged, Hungary Hosp Cent Asturias, Oviedo, Spain AstraZeneca, Macclesfield, Cheshire, England Asan Med Ctr, Seoul, South Korea Chang Gung Mem Hosp, Tao Yuan, Taiwan
- [29] TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients with DDR gene-mutated, metastatic castration-sensitive prostate cancer (mCSPC).JOURNAL OF CLINICAL ONCOLOGY, 2023, 41Agarwal, Neeraj论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USASaad, Fred论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USAAzad, Arun论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USAMateo, Joaquin论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USAMatsubara, Nobuaki论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USAShore, Neal D.论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USAChakrabarti, Jayeta论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USAChen, Hsiang-Chun论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USALanzalone, Silvana论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USANiyazov, Alexander论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USAFizazi, Karim论文数: 0 引用数: 0 h-index: 0机构: Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
- [30] PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)Kibel, Adam S.论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAGleave, Martin论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USABrookman-May, Sabine D.论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAKim, Won论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAEvans, Christopher P.论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAEfstathiou, Eleni论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAKantoff, Philip W.论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USARoss, Ashley论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAShore, Neal D.论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USABriganti, Alberto论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAHadaschik, Boris A.论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAHeidenreich, Axel论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USARooney, Oliver Brendan论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USATian, Shaozhou Ken论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAWetherhold, Lisa论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAXu, Weichun论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAParsons, J. Kellogg论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USAYeruva, Kesav论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USATaplin, Mary-Ellen论文数: 0 引用数: 0 h-index: 0机构: Brigham & Womens Hosp, Boston, MA USA